Medindia
Discover the benefits of premium membership Click Here
Medindia » Health Watch

Epithelioid Tumors Have Improved Chemotherapy Response

by Dr. Trupti Shirole on June 23, 2023 at 11:13 PM
Listen to this News

Highlights:

Patients diagnosed with mesothelioma may be perplexed by the number of tests ordered by their oncologist. While they may think of the disease in broad terms, there are major changes in therapy - and treatment success - depending on where the disease presents in the body and the type of cells that make up their tumors. A recent study found that cancers composed of epithelioid cells react better to chemotherapy than tumors composed of other cell types.


Epithelioid Mesothelioma and Higher Survival Rates

Malignant mesothelioma affects numerous sections of the body, and tumors can be made up of many types of cells. Pleural mesothelioma is the most common type of asbestos-related disease, and it occurs in the lining of the cavity surrounding the lungs, whereas peritoneal mesothelioma forms in the lining surrounding organs in the abdomen and pericardial mesothelioma tumors form in the lining of the cavity surrounding the heart.

‘Promising breakthrough for mesothelioma patients! Epithelioid tumors show improved responses to chemotherapy, leading to better survival rates. #Mesothelioma #CancerResearch #MedicalBreakthrough’

Mesothelioma tumors, no matter where they grow, are made up of cells that can take various shapes. The epithelioid cell type is the most prevalent, followed by the sarcomatoid cell type. Biphasic tumors comprise both types of cells. It has long been recognized that patients with epithelioid tumors had a higher chance of survival (1). A study undertaken by doctors at Barcelona's Hospital Universitari Vall d'Hebron may explain why.

Epithelioid Mesothelioma's Positive Response to Chemotherapy

Physicians who studied the data of 189 patients treated for pleural mesothelioma between 2002 and 2020 reported in the journal Nature that individuals with epithelioid tumors responded better to chemotherapy than those with other cell types. Patients with epithelioid cancer who received chemotherapy had a median progression-free survival of 4.8 months, while those with other cell types had a progression-free survival of 3.6 months.

Dr. Susana Cedres, the study's lead author, stated, "Median OS [overall survival] of epithelioid patients treated with first-line chemotherapy was 26.7 months versus 15.0 months in non-epithelioid patients." Patients with non-epithelioid tumors had a worse prognosis in our study."

Reference:
  1. Malignant Mesothelioma - (https:www.ncbi.nlm.nih.gov/books/NBK519530/)

Source: Medindia

Cite this Article

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Dr. Trupti Shirole. (2023, June 23). Epithelioid Tumors Have Improved Chemotherapy Response . Medindia. Retrieved on Nov 22, 2024 from https://www.medindia.net/news/healthwatch/epithelioid-tumors-have-improved-chemotherapy-response-212392-1.htm.

  • MLA

    Dr. Trupti Shirole. "Epithelioid Tumors Have Improved Chemotherapy Response ". Medindia. Nov 22, 2024. <https://www.medindia.net/news/healthwatch/epithelioid-tumors-have-improved-chemotherapy-response-212392-1.htm>.

  • Chicago

    Dr. Trupti Shirole. "Epithelioid Tumors Have Improved Chemotherapy Response ". Medindia. https://www.medindia.net/news/healthwatch/epithelioid-tumors-have-improved-chemotherapy-response-212392-1.htm. (accessed Nov 22, 2024).

  • Harvard

    Dr. Trupti Shirole. 2023. Epithelioid Tumors Have Improved Chemotherapy Response . Medindia, viewed Nov 22, 2024, https://www.medindia.net/news/healthwatch/epithelioid-tumors-have-improved-chemotherapy-response-212392-1.htm.

View Non AMP Site | Back to top ↑